Understanding the relationship between depression and heart disease to improve patient care

Major depressive disorder (MDD) is associated with an increased risk of cardiovascular disease (CVD) and CVD is associated with an increased risk of MDD. Why is this? And what are the implications for providing optimal management and improving outcomes for patients with comorbid MDD and CVD in clinical practice? These topics were explored in a presentation by Professor Andrea Fiorillo, Naples, Italy, at EPA 2022.

MDD and CVD are strongly linked

Up to one in every five hospitalized cardiac patients has MDD

Patients with cardiovascular disease (CVD) are three times more likely to have MDD than the general population;1 and among hospitalized cardiac patients up to 20% meet psychiatric criteria for MDD and up to 20% experience depressive symptoms,2 said Professor Fiorillo. Furthermore, MDD increases the risk of developing ischemic heart disease (hazard ration [HR] 1.63) and stroke (HR 1.94).3

 

The bidirectional association between MDD and CVD

MDD and CVD are systemic illnesses sharing interconnected feedback mechanisms

The higher risk of subsequent MDD among patients with CVD and the higher risk of CVD among patients with MDD has led researchers to suggest a bidirectional association between CVD and MDD,3 explained Professor Fiorillo.

Genetic, hormonal, and physiological factors overlap in both MDD and CVD pathophysiology,4 but although many biological and behavioural mechanisms have been investigated, none of them seem to account for more than a small proportion of the risk.5

Shared environmental factors appear to be the major link between comorbid CVD and MDD

Analyses of data from the UK Biobank have shown that a genetic risk score strongly associated with a higher risk of coronary heart disease is not associated with an increased risk of MDD.6 Instead the analyses suggest that shared environmental factors are the major link between comorbid CVD and MDD, and that interleukin-6, C-reactive protein, and triglycerides are causally linked to MDD.6

Both MDD and CVD are considered to be systemic syndromes with many interconnected feedback mechanisms, involving for example cortisol, monamines, hippocampal volume, neurodegeneration, and sleep deprivation,7 said Professor Fiorillo.

 

Implications for clinical practice

Timely treatment of MDD in CVD can improve outcomes

Timely treatment and prevention of MDD in CVD can improve both quality of life and longevity,8 and initiatives have been set up to encourage closer collaboration between psychiatrists and cardiologists,9,10 said Professor Fiorillo.

  • The World Psychiatric Association (WPA) Collaborating Centres have developed a 2021–2024 Work Plan focusing on multimorbidities in patients with severe mental disorders, in collaboration with the WPA Working Group on Physical Comorbidities led by Professor Norman Sartorius,9 former director of the World Health Organization's Division of Mental Health.
  • The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) has published a position statement on CVD and diabetes in people with severe mental illness to promote screening and treating patients with severe mental illness for CVD risk factors and diabetes and shared care between different healthcare professionals.10

Individualize treatments to avoid adverse effects that might aggravate MDD or CVD

A multidisciplinary approach for the management of comorbid MDD in patients with CVD is suggested, and care coordinators can facilitate the management using the collaborative care approach.11 Routine screening for MDD using the 2-item patient health questionnaire (PHQ-2) followed by focused screening with the PHQ-9 is recommended.11

Finally, treatments should be individualized and selected to avoid adverse effects that might aggravate MDD or cardiovascular disease,12 concluded Professor Fiorillo.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

IE-NPDEP-0038

References
  1. Chaddha A, Robinson EA, Kline-Rogers E, et al. Mental health and cardiovascular disease. Am J Med. 2016;129(11):1145–48.
  2. Frasure-Smith N, Lespérance F. Depression and coronary artery disease. Herz. 2006;31 Suppl 3:64–8.
  3. Wium-Andersen M, Wium-Andersen I, Prescott E, et al. An attempt to explain the bidirectional association between ischaemic heart disease, stroke and depression: A cohort and meta-analytic approach. Br J Psych. 2019;217(2):434–41.
  4. Bucciarelli V, Caterino AL, Bianco F, et al. Depression and cardiovascular disease: The deep blue sea of women's heart. Trends Cardiovasc Med. 2020;30(3):170–76.
  5. Carney, R., Freedland, K. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14:145–55.
  6. Khandaker GM, Zuber V, Rees JMB, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. Mol Psychiatry. 2020;25:1477–86.
  7. Wittenborn AK, Rahmandad H, Rick J, Hosseinichimeh N. Depression as a systemic syndrome: mapping the feedback loops of major depressive disorder. Psychol Med. 2016;46(3):551–62.
  8. Malik J, Sharif Khan H, Younus F, Shoaib M. From heartbreak to heart disease: A narrative review on depression as an adjunct to cardiovascular disease. Pulse (Basel). 2021;8(3–4):86-91.
  9. Fiorillo A, Bhui KS, Stein DJ, et al. The 2021-2024 Work Plan of WPA Collaborating Centres. World Psychiatry. 2021 Oct;20(3):457.
  10. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–24.
  11. Jha MK, Qamar A, Vaduganathan M, et al. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(14):1827–45.
  12. Kahl KG, Stapel B, Correll CU. Psychological and psychopharmacological interventions in psychocardiology. Front Psychiatry. 2022;13:831359.
You are leaving Progress in Mind
Hello
Please confirm your email
We are sending you a confirmation link to your email address.
In order to get the access, please, check your email and confirm your registration.
The information on this site is exclusively intended for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country